{"title":"Nivolumab-induced immune-mediated acute gastritis in a melanoma patient.","authors":"Faruk Tas, Emel Ahishali, Orhun Cig Taskin","doi":"10.1097/CMR.0000000000001034","DOIUrl":null,"url":null,"abstract":"<p><p>Immune-mediated acute gastritis (IMAG) is a rare side effect of nivolumab therapy. A 49-year-old patient with metastatic melanoma developed IMAG during nivolumab treatment. In the 5th month of treatment, the patient complained of epigastric pain, nausea, vomiting, loss of appetite, and weight loss. Esophagogastroduodenoscopy and biopsy were performed, and the diagnosis of IMAG was pathologically confirmed. In addition to the discontinuation of nivolumab treatment, proton pump inhibitor and corticosteroid treatment were administered, and the complaints of the patient disappeared after 1 week. Since nivolumab is frequently used in melanoma patients, IMAG should be considered and diagnostic procedures should be performed in patients with symptoms suggestive of acute gastritis during treatment, although it rarely develops.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"201-203"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CMR.0000000000001034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Immune-mediated acute gastritis (IMAG) is a rare side effect of nivolumab therapy. A 49-year-old patient with metastatic melanoma developed IMAG during nivolumab treatment. In the 5th month of treatment, the patient complained of epigastric pain, nausea, vomiting, loss of appetite, and weight loss. Esophagogastroduodenoscopy and biopsy were performed, and the diagnosis of IMAG was pathologically confirmed. In addition to the discontinuation of nivolumab treatment, proton pump inhibitor and corticosteroid treatment were administered, and the complaints of the patient disappeared after 1 week. Since nivolumab is frequently used in melanoma patients, IMAG should be considered and diagnostic procedures should be performed in patients with symptoms suggestive of acute gastritis during treatment, although it rarely develops.
期刊介绍：
Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
